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infiltration and serum interleukin- 6 (IL-6) levels (p-0.0001, p-0.01, respectively). MMP-9 levels were lower 
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Abstract
Multiple myeloma is characterized by accelerated pro-
duction of the proteolytic enzyme matrix metallo-
proteinase (MMP)-9. We hypothesized that mye-
loma-produced MMP-9 may influence the rate of bone
turnover in a paracrine manner. Thus, we examined
the correlations of MMP-9 levels, disease severity,
and bone turnover rate as evaluated by markers of
bone formation and resorption.
Thirty-seven newly diagnosed multiple myeloma
patients (nine of Durie-Salmon stage I, 12 of stage II
and 16 of stage III) and 12 age-matched controls were
studied. Serum MMP-9 levels were significantly high-
er at stage II compared to stage I (188.78"91.27 vs.
59.25"33.09 ng/mL, p-0.004). Additionally, free
urine pyridinolines (F-Pyd), free urine deoxy-pyridi-
nolines (F-Dpd) and urine N-telopeptide fragment
(NTx) were elevated, their level correlating with dis-
ease stage (p-0.001, p-0.03, p-0.001, respectively),
as were bone marrow infiltration and serum interleu-
kin-6 (IL-6) levels (p-0.0001, p-0.01, respectively).
MMP-9 levels were lower in patients compared with
controls (p-0.001), whereas IL-6 and bone resorption
marker levels were higher in patients than in controls
(p-0.001 in all cases). Significant correlation was
found between infiltration, MMP-9, free urine pyd,
free urine dpd and NTx for each stage of the disease
(p-0.03, p-0.003, p-0.002, p-0.003 and p-0.001,
respectively). Levels of MMP-9 and of IL-6 in multiple
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myeloma correlate well with bone turn-
over rate and may be useful in disease evaluation.
Keywords: matrix metalloproteinases; multiple mye-
loma; N-telopeptide.
Introduction
Multiple myeloma (MM) is a malignant monoclonal
proliferation of bone marrow plasma cells, with
debilitating skeletal involvement (1, 2). Skeletal mor-
bidity in MM correlates well with the degree of plas-
ma cell infiltration (3, 4). The progression of the
disease involves the production by the tumor cells
of a specific class of extracellular matrix-degrading
metalloenzymes, including matrix metalloproteinase
(MMP)-9, a 92-kDa type IV collagenase (5, 6). MMP-9
degrades collagen IV, the major constituent of base-
ment membrane, and this appears an essential step
for cellular invasion and tumor progression (7–9). The
pathogenesis of myeloma-induced bone disease is
associated with accelerated bone turnover, leading to
an imbalance between bone formation and resorption
(10). MMP-9 is predominantly expressed in cells of
macrophage lineage, such as osteoclasts that use it
to hydrolyze bone collagen type I (11, 12). It is pos-
tulated that myeloma cell-derived MMP-9 – produced
in the vicinity of bones – may enhance organic bone
matrix absorption in a direct, paracrine fashion (7, 13).
Malignant plasma cell infiltration has been shown to
be directly responsible for the increased resorptive
activity and abnormal remodeling, either by locally
produced autocrine or paracrine osteoclast-activating
factors or by direct cell to cell contact (1). Further-
more, the production of MMP-9 by myeloma cells
could be accelerated locally by cytokines, chemokines
and growth factors produced by bone cells, aggravat-
ing, thus, the invasive behavior of the malignant cells,
by the establishment of a local self-accelerating cycle
(14). Indeed, bone marrow endothelial cells were
found to enhance MMP-9 production in MM, indicat-
ing that endothelial cells accelerate MM cell invasion
via MMP-9 secretion (7, 13, 15). Bone formation and
resorption markers represent sensitive indices of the
rate of bone turnover (16–18). The aim of the present
work was to examine the levels of MMP-9 in patients
with MM and age-matched controls, and correlate
them to the severity of disease, as well as to the rate
of bone turnover. For this purpose, we measured
MMP-9 levels and bone resorption biochemical indi-
Sfiridaki et al.: Matrix metalloproteinase-9 in multiple myeloma 935
Article in press - uncorrected proof
Table 1 Values of plasma cell infiltration, IL-6, MMP-9, and of biochemical markers of bone resorption in 37 untreated MM
patients according to disease stage, and in controls. With the exception of MMP-9, values of all measured parameters were
significantly higher in MM patients than in controls. Values for infiltration, IL-6, and urinary N-telopeptide (NTx) were signi-
ficantly higher with advancing stage of the disease.
Multiple myeloma group Controls
Stage I Stage II Stage III
Mean ("SD) Mean ("SD) Mean ("SD)
Infiltration 22.56"16.09 33.58"19.78 56.25"16.78*
IL-6, pg/mL 3.06"1.33 5.71"3.48 9.47"6.79** 0.98"0.64q
MMP-9, ng/mL 59.25"33.09 188.78"91.27*** 131.2"96.32 289.8"110.46q
NTx 86"67.49 159"61.23 222.4"47.68* 32.67"3.11q
F-Pyd 26.6"6.5 54.3"19.6** 58.4"23.8* 20.83"2.62*
F-Dpd 5.7"1.6 12.3"5.3*** 11.9"5.3*** 4.17"0.72q
*Stage III vs. I and II p-0.001, **Stage III vs. I p-0.002, ***Stage II vs. I p-0.004, qcontrol group vs. multiple myeloma group
p-0.001.
ces in our patients, and correlated them with the
stage of their disease.
Materials and methods
Patients
The study population included 37 newly diagnosed patients
with MM: nine in stage I, 12 in stage II and 16 in stage III
according to Durie-Salmon classification (19). Serum sam-
ples from 12 persons, age- and sex-matched healthy volun-
teers, were used as controls. Informed consent for the study
was obtained from all subjects.
The median age of the patient group was 63 years (range
39–84 years). There were 17 males (age 39–81 years) and 20
females (age 39–81 years). Monoclonal immunoglobulins
IgG, IgA and light chain disease were found in 22, 11 and
four patients, respectively. No patient had received chemo-
therapy or radiotherapy prior to initial sampling. None of the
patients had evidence of thyroid or parathyroid hormone-
related abnormalities or had received any therapy known to
affect bone metabolism. According to standard X-ray eval-
uation of the patients, bone involvement was graded into
four scores: no lesions (score 0), one bone involved or dif-
fuse osteoporosis (score 1), more than one but less than four
bone lesions (score 2) and more than four bone lesions or
bone fracture present (score 3). Using these definitions, 11
patients had score 0, four had score 1, six had score 2, and
16 patients had score 3.
Methods
Serum samples were collected from patients and controls,
aliquoted into separate vials and stored at y708C after col-
lection, and assayed at the end of the study, in order to avoid
inter-assay variability.
Urinary N-telopeptide (NTx) cross-links of type I collagen
were measured by a competitive-inhibition enzyme-linked
immunosorbent assay (ELISA) (Osteomark Ostex Inter-
national, Seattle, WA, USA), using a monoclonal antibody
for NTx labeled with horseradish peroxidase. Results were
collected for 24-h urinary concentration of creatinine and
expressed as nanomoles of bone collagen equivalent per
millimole of creatinine (nmol BCE/mM creat). Free urine pyri-
dinolines (F-Pyd) were measured by a competitive enzyme
immunoassay (METRA PYD EIA assay, Metra biosystems,
Mountain View, CA, USA) using monoclonal antibodies. Free
urine deoxy-pyridinolines (F-Dpd) alone were measured by
METRA DPD EIA assay (Metra biosystems). Results for F-Pyd
and F-Dpd alone were corrected for 24-h urinary concentra-
tion of creatinine and expressed as nanomoles per millimole
of creatinine.
Measurements of IL-6 and MMP-9 in serum samples col-
lected from patients and controls were performed by solid-
phase sandwich ELISA with commercially available test kits,
Quantikine Human MMP-9 (total) and IL-6 (R&D Systems
Inc., Minneapolis, MN, USA).
Bone marrow cellularity and percentage of bone marrow
infiltration by myeloma cells was estimated by bone marrow
biopsies that were taken during local anesthesia from a point
below the iliac crest.
Statistical analysis
Results are expressed as mean"SD. The non-para-
metric Kruskal-Wallis test and one-way analysis of variance
(ANOVA) were assessed to test the existence of differences
between different stages. The Student-Newman-Keuls test
was used for pairwise comparison of subgroups. Statistical
comparisons between the MM group and the control group
were made using the non-parametric Mann-Whitney test.
Correlations between the various measured parameters
were calculated by Spearman’s rank correlation coefficient.
p-Values -0.05 were considered to be statistically signi-
ficant.
Results
The mean concentration of IL-6 in the entire group of
patients was 6.69"5.51 pg/mL and was significantly
higher in comparison to that found in the control
group (p-0.001) (Table 1). The mean values for infil-
tration and IL-6 in the group of MM patients were sig-
nificantly higher with increasing stage of disease
(p-0.001, p-0.01, respectively) (Table 1). Subse-
quently, we evaluated the measured parameters of
disease activity, infiltration and IL-6 according to the
grade of bone disease. Bone marrow infiltration was
significantly higher in grade 3 than in grade 0
(51.88"21.28 vs. 28"16.28, ps0.02). In contrast,
mean serum levels of IL-6 were higher with advancing
bone disease, but without statistical significance.
The mean concentrations of NTx, F-Pyd and F-Dpd
were significantly higher in MM patients in compari-
son to those found in the group of controls (p-0.001
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Figure 1 Correlation between serum MMP-9 levels and uri-
nary N-telopeptide (NTx) values in 37 newly diagnosed mul-
tiple myeloma patients. A significant positive correlation was
found between serum MMP-9 and NTx values (Spearman’s
correlation coefficient, rs0.340, p-0.04).
Figure 2 Serum MMP-9 levels and free urine pyridinoline
(F-Pyd) values in 37 newly diagnosed multiple myeloma
patients. There was a positive correlation between serum
MMP-9 and F-Pyd values, which did not reach statistical sig-
nificance (Spearman’s correlation coefficient, rs0.299,
ps0.07).
Figure 3 Serum MMP-9 levels and free urine deoxy-pyridi-
noline (F-Dpd) values in 37 newly diagnosed multiple mye-
loma patients. There was a positive correlation between
serum MMP-9 and F-Dpd values, which did not reach statis-
tical significance (Spearman’s correlation coefficient,
rs0.228, ps0.08).
in all cases) (Table 1). In the group of MM patients,
the mean concentrations of NTx, F-Pyd
and F-Dpd were significantly higher as the stage of
disease advanced (p-0.001, p-0.001, p-0.003, re-
spectively).
The biochemical parameters were analyzed accord-
ing to the severity of bone disease at diagnosis, as
estimated by radiographs of the whole skeleton
(grade 0 to 3). Patients with progressive bone disease
had elevated levels of F-Pyd and F-Dpd in comparison
to patients without osteolytic lesions. More specifi-
cally, the mean concentrations of F-Pyd and F-Dpd
were higher in grade 3 compared to grade 0
(61.81"22.17 vs. 30.55"15.91, p-0.002, and 13.13"
5.46 vs. 6.27"2.72, p-0.003, respectively). In con-
trast, the mean concentrations of F-Pyd and F-Dpd in
grades 0, 1 and 2 were increasing gradually with
advancing bone disease, but differences did not reach
statistical significance. Moreover, mean concentra-
tions of NTx were higher in grade 3 compared to
grades 0, 1 and 2 (p-0.001 in all cases).
We further evaluated the levels of MMP-9 in healthy
controls and in the group of patients. The mean
serum concentration of MMP-9 (132.37"95.14 ng/mL)
was lower in the group of patients compared to the
control group (289.80"110.46 ng/mL, p-0.001)
(Table 1). Furthermore, MMP-9 mean serum concen-
tration was significantly higher in stage II, in compar-
ison to stage I (p-0.004). Stratification of MMP-9
serum levels according to the grade of bone disease
revealed higher levels in grade 2 vs. grades 0 and 1
(p-0.003, p-0.02, respectively). Of note, a positive
correlation was found between infiltration and NTx
levels (rs0.340, p-0.03) as well as between serum
IL-6 and NTx levels (rs0.340, p-0.04). A significant
correlation was found between serum MMP-9 and
NTx values (rs0.340, p-0.04) (Figure 1). In addition,
a trend was detected between MMP-9 values and
F-Pyd and F-Dpd, which approached statistical signif-
icance (rs0.299, ps0.07 and rs0.228, ps0.08,
respectively) (Figures 2 and 3).
Discussion
We and others have shown that there is an enhance-
ment of osteoclastic activity in MM patients (3, 4, 20).
This process is mediated by factors produced locally
by malignant and non-malignant cells in the micro-
environment of bones. We have found that MMP-9
Sfiridaki et al.: Matrix metalloproteinase-9 in multiple myeloma 937
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may play an important role in worsening bone dis-
ease in patients with MM.
In the present study, serum levels of MMP-9 in sta-
ges II and III MM patients were higher than in stage I
patients, but serum MMP-9 levels in the whole patient
group were lower compared to the age-matched con-
trol group. The explanation for this discrepancy
remains unclear. In MM patients, reduced MMP-9 lev-
els have been detected in tumors with elevated levels
of syndecan-1 (21), however, decreased MMP-9 does
not result from association with syndecan-1 expres-
sion in malignant cells (22). Lower MMP-9 levels in
myeloma patients may be due to a reduction in MMP-
9 production from normal sources in MM, which leads
to a net decrease in serum MMP-9 (21). It has been
postulated that the predominant sources of serum
MMP-9 activity in normal people are the circulating
lymphocytes, neutrophils and monocytes in which
MMP-9 is thought to play an important physiological
role (23). As such cells may be crowded by malignant
plasma cells in MM, future relevant studies of MMP-9
levels from the bone lesions may help clarify this
issue. From this point of view, mast cells may also be
important as they have been reported to produce
MMP-9 (24), and mast cell chymase activates pro-
MMP-9 (25). Mast cell release of MMP-9 and other
lytic enzymes has been associated with tumor pro-
gression and aggressiveness (26).
The progression of the disease in MM patients is
accompanied by an accelerated angiogenesis and
production of proteolytic enzymes (6, 27). Further-
more, the growth of myeloma cells is regulated by a
cytokine network in which IL-6 represents a major
growth player. We found higher serum MMP-9 levels
in patients with bone disease scores 2 and 3, in com-
parison to scores 0 and 1. This observation suggests
that the excessive MMP-9 activity in bone marrow
plays a functional role in pathological conditions
associated with MM, such as tumor progression and
osteolysis.
We found that the levels of serum MMP-9 correlat-
ed significantly to the estimated rate of bone turn-
over. Indeed, we report a positive correlation between
urinary levels of NTx, MMP-9 (rs0.328, p-0.04) and
IL-6 (rs0.340, p-0.04). Based on this finding, we and
others postulate that the accelerated bone turnover is
a result of locally produced factors (including MMP-9)
in the microenvironment of the bone, which either
accelerate bone turnover (3) or enhance their biolog-
ical effect via MMP-9. In fact, our results show a trend
for direct association of MMP-9 values with F-Pyd and
F-Dpd suggesting the possible role of MMP-9, pro-
duced locally by myeloma cells, in the promotion of
osteolytic bone disease. Published reports suggest
that MMP-9 plays an important role in bone resorp-
tion (7, 16), and that MMP-9 production by plasma
cells accelerates invasiveness and angiogenesis (28).
The latter is related to the proliferative activity of
malignant plasma cells, according to our previous
results (29).
In the present study, serum levels of IL-6 correlated
well with urinary levels of NTx, and also, in contrast
with MMP-9, with disease stage, being significantly
higher in MM patients than in controls, confirming
previous results (29). Measurement, thus, of IL-6 may
provide a useful marker for monitoring disease acti-
vity in MM. Interestingly, serum IL-6 levels have been
reported to correlate well with bone involvement in
systemic mastocytosis patients (30).
We have found that the mean concentrations of
NTx, F-Pyd and F-Dpd were significantly higher in the
MM patients compared to age-matched healthy con-
trols (p-0.001). Moreover, in the group of MM
patients the mean concentrations of NTx, F-Pyd and
F-Dpd were increasing significantly as the disease
progressed (p-0.001, p-0.001, p-0.003,
respectively).
Finally, biochemical parameters were found to cor-
relate to the severity of bone disease at diagnosis, as
estimated by X-rays. Thus, patients with progressive
bone disease had elevated levels of F-Pyd and F-Dpd
compared to patients without osteolytic lesions. Spe-
cifically, mean concentrations of F-Pyd and F-Dpd
were higher in grade 3 than in grade 0 (61.81"22.17
vs. 30.55"15.91, p-0.002, and 13.13"5.46 vs.
6.27"2.72, p-0.003, respectively).
In conclusion, we have found that levels of MMP-9
and of IL-6 in the circulation of patients with MM cor-
relate with both the radiological disease score and the
rate of bone turnover as judged by biochemical mark-
ers of bone resorption and formation. Based on these
findings, we propose measuring the levels of MMP-9
in the blood of patients with MM, since this determi-
nation may add information regarding the severity of
their disease and the degree of its effect on bone well
being.
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